好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

2025 Fall Conference | Industry Therapeutic Update from Lilly: Clinical Decision Making with Kisunla (donanemab-azbt).

Saturday 11/08/25
12:00 PM - 01:00 PM PDT Add To Calendar
This program will be presented in-person only
This program is not expected to be available in the meeting's On Demand product.
Industry Therapeutic Update
Burton J. Tabaac, MD
Aging, Dementia, and Behavioral Neurology, General Neurology
Join us for an educational session where we will discuss how to identify appropriate patients, efficacy and established safety profile from our latest clinical trials. Please see the Important Safety Information, including Boxed Warning regarding ARIA, the Full Prescribing Information, and Medication Guide provided at the Product Theater and at https://kisunla.lilly.com/hcp. This program is sponsored by, and the speaker is presenting on behalf of, Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit. This program is not accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2025 Fall Conference education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.
No CME available

Program Materials Program Evaluations

Event Timeline
12:00 PM - 01:00 PM PDT Speaker Industry Therapeutic Update from Lilly: Clinical Decision Making with Kisunla (donanemab-azbt)
Burton J. Tabaac, MD
Faculty Disclosures
Burton J. Tabaac, MD No disclosure on file